Targeting CDK7 reverses tamoxifen resistance through regulating stemness in ER+ breast cancer

被引：0
作者：
Yasmin M. Attia
Salama A. Salama
Samia A. Shouman
Cristina Ivan
Abdelrahman M. Elsayed
Paola Amero
Cristian Rodriguez-Aguayo
Gabriel Lopez-Berestein
机构：
[1] Cairo University,Pharmacology and Experimental Therapeutics Unit, Cancer Biology Department, National Cancer Institute
[2] Al-Azhar University,Pharmacology and Toxicology Department, Faculty of Pharmacy
[3] The University of Texas MD Anderson Cancer Center,Department of Experimental Therapeutics
[4] The University of Texas MD Anderson Cancer Center,Center for RNA Interference and Non
[5] The University of Texas MD Anderson Cancer Center,Coding RNA
来源：
Pharmacological Reports | 2022年 / 74卷
关键词：
Breast cancer; Cancer stem cells; Tamoxifen; Cyclin-dependent kinase; SOX2;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：366 / 378
页数：12
相关论文
共 50 条
  • [31] Brachyury promotes tamoxifen resistance in breast cancer by targeting SIRT1
    Li, Kaichun
    Ying, Mingzhen
    Feng, Dan
    Du, Jie
    Chen, Shiyu
    Dan, Bing
    Wang, Cuihua
    Wang, Yajie
    BIOMEDICINE & PHARMACOTHERAPY, 2016, 84 : 28 - 33
  • [32] p53-GSDME Elevation: A Path for CDK7 Inhibition to Suppress Breast Cancer Cell Survival
    Wang, Yueyuan
    Peng, Jingyu
    Mi, Xuguang
    Yang, Ming
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2021, 8
  • [33] miR-221/222 sponge abrogates tamoxifen resistance in ER-positive breast cancer cells through restoring the expression of ERα
    Ouyang, Yan Xiu
    Feng, Jun
    Wang, Zun
    Zhang, Guo Jun
    Chen, Min
    MOLECULAR BIOMEDICINE, 2021, 2 (01):
  • [34] miR-221/222 sponge abrogates tamoxifen resistance in ER-positive breast cancer cells through restoring the expression of ERα
    Yan Xiu Ouyang
    Jun Feng
    Zun Wang
    Guo Jun Zhang
    Min Chen
    Molecular Biomedicine, 2
  • [35] Tumorigenic risk of Angelica sinensis on ER-positive breast cancer growth through ER-induced stemness in vitro and in vivo
    Zhu, Hongni
    You, Jeishu
    Wen, Yi
    Jia, Lei
    Gao, Fei
    Ganesan, Kumar
    Chen, Jianping
    JOURNAL OF ETHNOPHARMACOLOGY, 2021, 280
  • [36] Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer
    Mao, Pingping
    Cohen, Ofir
    Kowalski, Kailey J.
    Kusiel, Justin G.
    Buendia-Buendia, Jorge E.
    Cuoco, Michael S.
    Exman, Pedro
    Wander, Seth A.
    Waks, Adrienne G.
    Nayar, Utthara
    Chung, Jon
    Freeman, Samuel
    Rozenblatt-Rosen, Orit
    Miller, Vincent A.
    Piccioni, Federica
    Root, David E.
    Regev, Aviv
    Winer, Eric P.
    Lin, Nancy U.
    Wagle, Nikhil
    CLINICAL CANCER RESEARCH, 2020, 26 (22) : 5974 - 5989
  • [37] Targeting focal adhesion kinase in ER+/HER2+breast cancer improves trastuzumab response
    Lazaro, Glorianne
    Smith, Chris
    Goddard, Lindy
    Jordan, Nicola
    McClelland, Richard
    Barrett-Lee, Peter
    Nicholson, Robert I.
    Hiscox, Stephen
    ENDOCRINE-RELATED CANCER, 2013, 20 (05) : 691 - 704
  • [38] miR-7 Reverses Breast Cancer Resistance To Chemotherapy By Targeting MRP1 And BCL2
    Hong, Tianzi
    Ding, Jian
    Li, Wenlian
    ONCOTARGETS AND THERAPY, 2019, 12 : 11097 - 11105
  • [39] A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2-breast cancer
    Servetto, Alberto
    Napolitano, Fabiana
    Angelis, Carmine De
    Placido, Pietro De
    Giuliano, Mario
    Arpino, Grazia
    Placido, Sabino De
    Bianco, Roberto
    Formisano, Luigi
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 157
  • [40] Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance to Endocrine Therapy and CDK4/6 Inhibitors in Advanced ER+/HER2-Breast Cancer
    Ferrari, Paola
    Schiavone, Maria Luisa
    Scatena, Cristian
    Nicolini, Andrea
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (07)
12345